SAFC and Novozymes Biopharma have agreed to extend their partnership by ten years for the exclusive distribution of LONG R3 growth factor, used for industrial cell culture applications.
Revenues fell 3 per cent in 2009 at SAFC but pharmaceutical sector demand for vaccine manufacturing products helped firm finish year with six months of growth.
Sigma-Aldrich Group member SAFC made its presence felt at the
recent CPhI in Paris with announcements regarding its expansion
activities in transgenic manufacturing and India.